Program Description:
Although there have been advances in treatment, the incidence, morbidity, and mortality associated with acute coronary syndrome (ACS) remain significant. Therapy for ACS utilizes a combination of surgical interventions (including percutaneous coronary interventions [PCI]) and pharmacotherapy, with antiplatelet agents playing an essential role. There may be significant risks with these interventions, during the procedure itself and in the months and years following. Ischemic events can continue to occur, despite the use of either standard antiplatelet therapy or variations in dosages and combinations of agents.
Target Audience: Primary Care Physicians
Activity Objectives:
At the conclusion of this activity, participants will be better able to:
- Discuss current approaches to the management of patients with acute coronary syndrome (ACS), particularly those undergoing percutaneous coronary intervention (PCI)
- Review the current guidelines of the American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions regarding use of dual antiplatelet therapy to prevent myocardial infarction (MI) and death in patients following PCI
- Explain the concept of thienopyridine “resistance,” and recognize its potential implications for secondary prevention in patients post-ACS
- Evaluate emerging options for antiplatelet therapy post-ACS, including new thienopyridines, non-thienopyridines, and other agents, taking into consideration their safety, efficacy, and mechanisms of action
|
Credits
|
Type
|
Accreditation Statement
|
Designation Statement
|
|
2.00
|
AMA PRA Category 1 Credit(s)TM
|
Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
|
Albert Einstein designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
|
Faculty:
FACULTY CHAIR
James A. de Lemos, MD
Associate Professor
Internal Medicine – Cardiology
Southwestern Medical School
Cardiology Division
UT Southwestern Medical Center
Dallas, TX
EDITORIAL BOARD
Jarett D. Berry, MD, MS
Assistant Professor, Internal Medicine – Cardiology
Southwestern Medical School
Cardiology Division
UT Southwestern Medical Center
Dallas, TX
Benjamin M. Scirica, MD, MPH
TIMI Study Group
Cardiovascular Division
Brigham and Women's Hospital
Boston, MA
COURSE DIRECTOR
E. Scott Monrad, MD
Professor of Clinical Medicine
Albert Einstein College of Medicine
Director, Cardiac Catheterization Laboratory
Einstein Division, Montefiore Medical Center
Bronx, NY
Disclosures:
James A. de Lemos, MD, has received speakers’ honoraria from Merck/Schering, Pfizer Inc, and sanofi-aventis-Bristol Myers Squibb partnership; consulting fees from Biosite, Roche, and Pfizer Inc; and research grants from Biosite.
Jarett D. Berry, MD, MS, has received speakers’ honoraria from Merck/Schering.
Benjamin M. Scirica, MD, MPH, has received grants/research support from CV Therapeutics, Inc.; Novartis; AstraZeneca; and Daiichi Sankyo, Inc.; and consulting fees from CV Therapeutics, Inc.; AstraZeneca; and Merck & Co., Inc.
E. Scott Monrad, MD, has no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Albert Einstein College of Medicine of Yeshiva University, Daiichi Sankyo Lilly, and Haymarket Medical Education do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Albert Einstein College of Medicine of Yeshiva University, Daiichi Sankyo Lilly, and Haymarket Medical Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Supported by an educational grant from Daiichi Sankyo and Lilly USA, LLC.
Sponsored by Albert Einstein College of Medicine of Yeshiva University.
Instructions:
To obtain credit, a score of 70% or better is required. This CME is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.
SYSTEM REQUIREMENTS:
WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution
set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.
MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20
MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands
of Colors”; Macromedia Flash Player 6 or higher.